Gland Pharma IPO GMP Today, Gland Pharma IPO Grey Market Premium Updates | Gland Pharma IPO Listing Gain, Latest target, Opening gain.
Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. The price band for the offer has been fixed at Rs 1,490-1,500 per share. The issue will close on 11 November.
The Gland Pharma IPO, India’s largest IPO in the pharmaceutical sector, comprises a fresh issue aggregating up to Rs 1,250 crore and an offer for sale of up to 3.49 crore shares.
Check out the latest Gland Pharma IPO GMP (Grey Market Premium), Kostak rates and Subject to Sauda rates here.
Gland Pharma IPO Details:
|Issuer||Gland Pharma Ltd.|
|Issue Type||Book Built Issue IPO|
|Issue Period||Issue Opens: November 9, 2020|
|Issue Closes: November 11, 2020|
|Price Brand||₹1490 – 1500 Equity share|
|Issue Size||₹6500 Crores (Approx.)|
|Face Value||Rs.1 per Equity Share|
|Market Lot||10 Shares and in multiples thereof|
|Maximum Bid amount for Retail||Rs. 2 Lakhs|
|QIB||50% of the issue size|
|NIB||15% of the issue size|
|Retail Individual Bidders||35% of the issue size|
|Offer for Sale||34,863,635 shares
(INR5,194.68 – 5,229.55 crore)
|Fresh Issue||₹1250 Cr (Expected)|
|Listing at||NSE & BSE|
|Apply With||Upstox Free DEMAT Account|
|RailTel IPO GMP Today|
|Grey Market Price||Latest IPO GMP|
Gland Pharma IPO Listing
Gland Pharma IPO GMP Rates day by day
|Date||GMP (in INR)||Kostak (in INR)||Subject to Sauda|
|20 Nov 2020|
|19 Nov 2020||140||1000||500|
|18 Nov 2020||140||1000||N/A|
|17 Nov 2020||70||N/A||N/A|
|16 Nov 2020||50||N/A||N/A|
|15 Nov 2020||10||N/A||N/A|
|14 Nov 2020||10||N/A||N/A|
|13 Nov 2020||10||N/A||N/A|
|12 Nov 2020||20||N/A||N/A|
|11 Nov 2020||25||200||N/A|
|10 Nov 2020||25||200||N/A|
|9 Nov 2020||70||500||2000|
|8 Nov 2020||70||500||2000|
|6 Nov 2020||70||500||2000|
|5 Nov 2020||80||500||1,000|
|4 Nov 2020||170||800||1,200|
|3 Nov 2020||160||700||1,100|
|2 Nov 2020||150||700||1,100|
Gland Pharma IPO Market Lot:
|Lot Size:||Minimum 10 Shares & Maximum 130 Shares|
Gland Pharma IPO Review
Gland Pharma IPO Allotment & Listing:
|Basis of Allotment:||November 17, 2020|
|Refunds:||November 18, 2020|
|Credit to Demat Account:||November 19, 2020|
|Listing Date:||November 20,2020|
– IPO Grey Market Premium (IPO GMP) mention is valid for the specific date as mentioned in the header.
– We are not buying and selling IPO forms on IPO Grey Market.
– Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
– Do not subscribe for IPO by just seeing premium Price as it may change anytime before listing. Subscribe only considering Fundamental of the companies
IPO GMP rates are provided as sourced from market intelligence. Please note these IPO GMP rates may be different depending on geographies and markets.
We don’t trade into grey market nor do we facilitate buying or selling of IPO forms.
UPCOMING IPO IN NOVEMBER 2020
What is Grey Market?
Grey Market is the term used to describe unregulated over-the-counter market for trading IPO applications and IPO shares before the stock is listed at a stock market. This is a way for dealers to support their customers who may want to exit before listing.
This is also a way to boost the listing price and support the issue before listing happens. There are two kinds of transactions that happen in thee IPO grey market:
- Trade of IPO shares at a grey market premium
- Trade of IPO application at a kostak.
What is Grey Market Premium?
GMP or Grey Market Premium is the premium at which equity shares from the IPO are being traded in the grey market.
This could either be a positive or negative – meaning the trading price in the grey market is either higher or lower than issue price respectively, based on demand and supply for the shares.
Typically, investors who do not want to take the risk of allocation not happening through IPO will buy shares in the gray market and hope to flip the shares on listing to make a good profit.
What is Kostak?
Kostak is the premium at which IPO application is being traded in the grey market. Applications are typically traded after the application window is closed but the allotment has not yet been finished.
It is rare for someone to trade IPO application post-allocation. This is a way for investors to increase their chance of shares being allotted as the allocation process treats each retail application equally. An example (indicative) for kostak is:
– IGL Limited
– Issue Price: Rs 480 Per Equity Share (at upper band)
– Lot Size: 14
– Grey Market Premium: Rs 350 to Rs 360
– Kostak (Rs 100000): Rs 2500 to Rs 2600
As can be seen the Kostak is at a much lower %age than GMP. This indicates that the grey market expects the issue to be oversubscribed and expects on an average only one lot to be allocated per application.
Kostak rate is the amount an investor gets by selling his/her IPO application in grey market. This is the amount an investor stands to gain, irrespective of allotment status.
Subject to Sauda simply reflects the amount which an investor stands to get by selling his/her application for firm allotment. The key operative word here is firm allotment. In case of no allotment to the applicant, the sauda stands cancelled.
In case of ‘Subject to Sauda’ deal, while selling IPO application in the grey market, buyer and seller agree that deal is only valid if the seller will get the allotment. If the seller doesn’t get any shares in IPO process, the deal gets avoid.
GLAND PHARMA IPO GMP FAQs
The Grey Market Premium of Gland Pharma IPO is approx in between Rs.1500 – 2000/- at the moment.
The Subject to Sauda price for Gland Pharma IPO is approx. Rs. 1200/-
It will be approx. Rs.2500/- (update on a daily basis)
The Kostak price of Gland Pharma IPO is approx. Rs 800/-.